Literature DB >> 8245534

Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections.

M T Niu1, D S Stein, S M Schnittman.   

Abstract

Primary human immunodeficiency virus type 1 (HIV-1) infection can present clinically as the abrupt onset of a febrile illness resembling acute mononucleosis. The symptoms coincide with high titers of culturable plasma viremia, cell-associated virus, and antigenemia, which rapidly decrease coincident with the emergence of detectable HIV-specific antibody and HIV-specific cytotoxic T lymphocytes. This article reviews the human and animal model data on the virologic and immunologic events that occur during primary HIV-1 and animal retrovirus infections, evaluates the prophylactic treatment experience of retrovirus infections in the animal model, and provides a plausible rationale for treatment intervention of primary HIV-1 infection in humans. Recent work delineating the pathogenesis of primary HIV-1 infection provides insight into the major mechanisms of viral dissemination and host immune response. The results from retrovirus-infected animal models treated with antiviral agents suggests that therapy at the time of viral dissemination may be an effective strategy that may modify disease progression. Clinical trials to evaluate this approach are in progress.

Entities:  

Mesh:

Year:  1993        PMID: 8245534     DOI: 10.1093/infdis/168.6.1490

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Primary HIV.

Authors:  J Fox; J Weber; S Fidler
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

Review 2.  AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung.

Authors:  J R Clarke; D S Robinson; R J Coker; R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

3.  Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques.

Authors:  M Wallace; P M Waterman; J L Mitchen; M Djavani; C Brown; P Trivedi; D Horejsh; M Dykhuizen; M Kitabwalla; C D Pauza
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Cocaine enhances HIV-1-induced CD4(+) T-cell apoptosis: implications in disease progression in cocaine-abusing HIV-1 patients.

Authors:  Jui Pandhare; Amma B Addai; Chinmay K Mantri; Cynthia Hager; Rita M Smith; Louis Barnett; Fernando Villalta; Spyros A Kalams; Chandravanu Dash
Journal:  Am J Pathol       Date:  2014-01-31       Impact factor: 4.307

5.  Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy.

Authors:  Daniel S Green; David M Center; William W Cruikshank
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 6.  HIV preventive vaccines. Progress to date.

Authors:  J Esparza; S Osmanov; W L Heyward
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

Review 7.  Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses.

Authors:  C B Hicks; C Gay; G Ferrari
Journal:  Clin Exp Immunol       Date:  2007-06-21       Impact factor: 4.330

8.  Immune activation and viral burden in acute disease induced by simian immunodeficiency virus SIVsmmPBj14: correlation between in vitro and in vivo events.

Authors:  R Schwiebert; P N Fultz
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus.

Authors:  A A Lackner; P Vogel; R A Ramos; J D Kluge; M Marthas
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

10.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.